The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nekrasova L.A.

Lomonosov Moscow State University

Nesterova O.Yu.

Lomonosov Moscow State University

Samokhodskaya L.M.

Lomonosov Moscow State University

Semina E.V.

Lomonosov Moscow State University;
Chazov National Medical Research Centre of Cardiology

Kamalov A.A.

Lomonosov Moscow State University

Relationship of fibrinolysis system proteins with severity of COVID-19. A review of current clinical data and promising therapeutic strategies

Authors:

Nekrasova L.A., Nesterova O.Yu., Samokhodskaya L.M., Semina E.V., Kamalov A.A.

More about the authors

Journal: Russian Cardiology Bulletin. 2022;17(3): 29‑38

DOI: 10.17116/Cardiobulletin20221703129

Read: 2142 times

Download PDF (RU)
Contact the author
Table of contents

RELATIONSHIP OF FIBRINOLYSIS SYSTEM PROTEINS WITH SEVERITY OF COVID-19. A REVIEW OF CURRENT CLINICAL DATA AND PROMISING THERAPEUTIC STRATEGIES
RELATIONSHIP OF FIBRINOLYSIS SYSTEM PROTEINS WITH SEVERITY OF COVID-19. A REVIEW OF CURRENT CLINICAL DATA AND PROMISING THERAPEUTIC STRATEGIES

To cite this article:

Nekrasova LA, Nesterova OYu, Samokhodskaya LM, Semina EV, Kamalov AA. Relationship of fibrinolysis system proteins with severity of COVID-19. A review of current clinical data and promising therapeutic strategies. Russian Cardiology Bulletin. 2022;17(3):29‑38. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20221703129

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diffuse changes in the brain in the acute phase of COVID-19 and after infe­ction. Russian Journal of Archive of Pathology. 2025;(1):5-15
Liver pathology in COVID-19. Russian Journal of Archive of Pathology. 2025;(1):53-59
A clinical case of the aortic rupture after SARS-CoV-2 in the patient with Stickler syndrom. Russian Journal of Preventive Medi­cine. 2025;(3):103-106
Post-COVID syndrome: orga­nizing COVID-19-associated pneumonia. Clinical case. Journal of Respiratory Medi­cine. 2025;(1):65-72
Coro­navirus infe­ction as a risk factor in occlusive-stenotic lesions of the brachiocephalic arte­ries. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):44-52
mRNA cancer vaccines: features of problems and collisions. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):3-16
SpO2/RR index in choosing the method for correction of acute respiratory failure in COVID-19 patients. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):50-58
Post-Covid aortitis with cardiac invo­lvement: progressive aortic aneurysm combined with active myocarditis. Russian Journal of Archive of Pathology. 2025;(2):53-58
Prediction and prevention of burnout syndrome in health care professionals in high epidemic risk settings. Russian Journal of Preventive Medi­cine. 2025;(4):51-56
Impact of the COVID-19 epidemic on students’ health. Part II. Features of hemo­dynamics, vege­tative regu­lation, resu­lts of psychological and stress resi­stance testing among students depe­nding on the COVID-19 presence in their medi­cal history. Russian Journal of Preventive Medi­cine. 2025;(4):94-101
Abstract:

Modern clinical studies show the association of fibrinolysis system factors with complications following COVID-19. This review includes the studies describing the relationship of urokinase plasminogen activator proteins uPA and its receptor uPAR, plasminogen activator inhibitor PAI-1 and plasmin itself with severity of COVID-19. Potential of diagnosis based on analysis of concentrations and activities of these proteins, as well as expression of their encoding genes is described. These data can predict severe course and possible complications of COVID-19 including thrombosis, respiratory failure and cytokine storm.

Keywords:

fibrinolysis system
urokinase
urokinase receptor
plasmin
plasminogen activator inhibitor
COVID-19

Authors:

Nekrasova L.A.

Lomonosov Moscow State University

Nesterova O.Yu.

Lomonosov Moscow State University

Samokhodskaya L.M.

Lomonosov Moscow State University

Semina E.V.

Lomonosov Moscow State University;
Chazov National Medical Research Centre of Cardiology

Kamalov A.A.

Lomonosov Moscow State University

Received:

01.07.2022

Accepted:

01.08.2022

Close metadata

References:

  1. D’Alonzo D, De Fenza M, Pavone V. COVID-19 and pneumonia: a role for the uPA/uPAR system. Drug Discovery Today. 2020;25(8):1528-1534. https://doi.org/10.1016/j.drudis.2020.06.013
  2. Páramo JA. Microvascular thrombosis and clinical implications. Medicina Clinica. 2021;156(12):609-614.  https://doi.org/10.1016/j.medcli.2020.12.042
  3. Hou Y, Ding Y, Nie H, Ji H-L. Fibrinolysis influences SARS-CoV-2 infection in ciliated cells. bioRxiv. 2021;2021.01.07.425801  https://doi.org/10.1101/2021.01.07.425801
  4. Panigada M, Meli A, Properzi P, Grasselli G, Iapichino GE. Normal Response to Fibrinolytic Challenge in COVID-19 Patients: Viscoelastic Evaluation Using Urokinase-Modified Thromboelastography. Journal of the American College of Surgeons. 2021;232(5):803-805.  https://doi.org/10.1016/j.jamcollsurg.2021.02.004
  5. Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection. Journal of Virology. 2019;93(6):e01815-1818. https://doi.org/10.1128/JVI.01815-18
  6. Huggins D.J. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2. Journal of Molecular Graphics & Modelling. 2020;100:107710. https://doi.org/10.1016/j.jmgm.2020.107710
  7. Mast AE, Wolberg AS, Gailani D, Garvin MR, Alvarez C, Miller JI, Aronow B, Jacobson D. SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. eLife. 2021;10:e64330. https://doi.org/10.7554/eLife.64330
  8. Lomholt AF, Høyer-Hansen G, Nielsen HJ, Christensen IJ. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. British Journal of Cancer. 2009;101(6):992-997.  https://doi.org/10.1038/sj.bjc.6605228
  9. Reisinger AC, Niedrist T, Posch F, Hatzl S, Hackl G, Prattes J, Schilcher G, Meißl A-M, Raggam RB, Herrmann M, Eller P. Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit. Scientific Reports. 2021;11(1):17476. https://doi.org/10.1038/s41598-021-96352-1
  10. Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Critical Care. 2020;24(1):187.  https://doi.org/10.1186/s13054-020-02897-4
  11. Arnold DT, Attwood M, Barratt S, Morley A, Elvers KT, McKernon J, Donald C, Oates A, Noel A, MacGowan A, Maskell NA, Hamilton FW. Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study. Emergency Medicine Journal. 2021;38(7):543-548.  https://doi.org/10.1136/emermed-2020-210380
  12. Oulhaj A, Alsuwaidi AR, Suliman A, Gasmelseed H, Khan S, Alawi S, Hukan Y, George J, Alshamsi F, Sheikh F, Babiker ZOE, Prattes J, Sourij H. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. International Journal of Infectious Diseases. 2021;107:188-194.  https://doi.org/10.1016/j.ijid.2021.04.026
  13. Azam TU, Shadid HR, Blakely P, O’Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami M-E, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS, International Study of Inflammation in COVID-19. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. Journal of the American Society of Nephrology. 2020;31(11):2725-2735. https://doi.org/10.1681/ASN.2020060829
  14. Huang M, Li L, Shen J, Wang Y, Wang R, Yuan C, Jiang MHL. Plasma levels of the active form of suPAR are associated with COVID-19 severity. Critical Care. 2020;24(1):704. 
  15. Keskinidou C, Vassiliou AG, Zacharis A, Jahaj E, Gallos P, Dimopoulou I, Orfanos SE, Kotanidou A. Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone. Diagnostics (Basel). 2021;11(7):1249. https://doi.org/10.3390/diagnostics11071249
  16. de Bruin S, Bos LD, van Roon MA, Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA, Bogaard HJ, Tuinman PR, van Agtmael MA, Hamann J, Teunissen CE, Wiersinga WJ, Zwinderman AHK, Brouwer MC, van de Beek D, Vlaar APJ, Amsterdam UMC COVID-19 Biobank Investigators. Clinical features and prognostic factors in Covid-19: A prospective cohort study. EBioMedicine. 2021;67:103378. https://doi.org/10.1016/j.ebiom.2021.103378
  17. Kerget B, Kerget F, Aksakal A, Aşkın S, Uçar EY, Sağlam L. Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR. Journal of Medical Virology. 2021;93(9):5568-5573. https://doi.org/10.1002/jmv.27099
  18. Lippi G, Henry BM, Favaloro EJ. Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients. Clinical Chemistry and Laboratory Medicine. 2021;59(11):413-415.  https://doi.org/10.1515/cclm-2021-0561
  19. Velissaris D, Lagadinou M, Paraskevas T, Oikonomou E, Karamouzos V, Karteri S, Bousis D, Pantzaris N, Tsiotsios K, Marangos M. Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study. Journal of Clinical Medicine Research. 2021;13(9):474-478.  https://doi.org/10.14740/jocmr4579
  20. Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, Madison JA, Knight JS, Kanthi Y, Lawrence DA. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Scientific Reports. 2021;11(1):1580. https://doi.org/10.1038/s41598-020-80010-z
  21. Whyte CS, Simpson M, Morrow GB, Wallace CA, Mentzer AJ, Knight JC, Shapiro S, Curry N, Bagot CN, Watson H, Cooper JG, Mutch NJ. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. Journal of Thrombosis and Haemostasis. 2022;10.1111/jth.15806. https://doi.org/10.1111/jth.15806
  22. Marchetti M, Gomez-Rosas P, Russo L, Gamba S, Sanga E, Verzeroli C, Ambaglio C, Schieppati F, Restuccia F, Bonanomi E, Rizzi M, Fagiuoli S, D’Alessio A, Gerotziafas GT, Lorini L, Falanga A. Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine. 2022;9:896362. https://doi.org/10.3389/fcvm.2022.896362
  23. Hammer S, Häberle H, Schlensak C, Bitzer M, Malek NP, Handgretinger R, Lang P, Hörber S, Peter A, Martus P, Mirakaj V, Gawaz M, Geisler T, Althaus K, Rosenberger P, Bakchoul T. Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19. Thrombosis and Haemostasis. 2021;121(11):1417-1426. https://doi.org/10.1055/a-1400-6034
  24. Tsantes AE, Frantzeskaki F, Tsantes AG, Rapti E, Rizos M, Kokoris SI, Paramythiotou E, Katsadiotis G, Karali V, Flevari A, Chrysanthopoulou E, Maratou E, Kyriakou E, Gialeraki A, Bonovas S, Dimopoulos G, Tsangaris I, Armaganidis A. The haemostatic profile in critically ill COVID-19 patients receiving therapeutic anticoagulant therapy: An observational study. Medicine (Baltimore). 2020;99(47):e23365. https://doi.org/10.1097/MD.0000000000023365
  25. Bauer W, Galtung N, Neuwinger N, Kaufner L, Langer E, Somasundaram R, Tauber R, Kappert K. A Matter of Caution: Coagulation Parameters in COVID-19 Do Not Differ from Patients with Ruled-Out SARS-CoV-2 Infection in the Emergency Department. TH Open. 2021;5(1):43-55.  https://doi.org/10.1055/s-0040-1722612
  26. Guervilly C, Bonifay A, Burtey S, Sabatier F, Cauchois R, Abdili E, Arnaud L, Lano G, Pietri L, Robert T, Velier M, Papazian L, Albanese J, Kaplanski G, Dignat-George F, Lacroix R. Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19. Blood Advances. 2021;5(3):628-634.  https://doi.org/10.1182/bloodadvances.2020003308
  27. Wu D, Yang XO. Dysregulation of Pulmonary Responses in Severe COVID-19. Viruses. 2021;13(6):957.  https://doi.org/10.3390/v13060957
  28. Jover E, Matilla L, Garaikoetxea M, Fernández-Celis A, Muntendam P, Jaisser F, Rossignol P, López-Andrés N. Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein. Biomedicines. 2021;9(6):639.  https://doi.org/10.3390/biomedicines9060639
  29. Hardy M, Michaux I, Lessire S, Douxfils J, Dogné J-M, Bareille M, Horlait G, Bulpa P, Chapelle C, Laporte S, Testa S, Jacqmin H, Lecompte T, Dive A, Mullier F. Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. Data in Brief. 2020;33:106519. https://doi.org/10.1016/j.dib.2020.106519
  30. Hardy M, Michaux I, Lessire S, Douxfils J, Dogné J-M, Bareille M, Horlait G, Bulpa P, Chapelle C, Laporte S, Testa S, Jacqmin H, Lecompte T, Dive A, Mullier F. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thrombosis Research. 2021;197:20-23.  https://doi.org/10.1016/j.thromres.2020.10.025
  31. Pine AB, Meizlish ML, Goshua G, Chang C-H, Zhang H, Bishai J, Bahel P, Patel A, Gbyli R, Kwan JM, Won CH, Price C, Cruz CSD, Halene S, van Dijk D, Hwa J, Lee AI, Chun HJ. Circulating markers of angiogenesis and endotheliopathy in COVID-19. Pulmonary Circulation. 2020;10(4):2045894020966547. https://doi.org/10.1177/2045894020966547
  32. Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Lonati P, Grossi C, Borghi MO, Novembrino C, Boscolo M, Renteria SCU, Valenti L, Lamorte G, Manunta M, Prati D, Pesenti A, Blasi F, Costantino G, Gori A, Bandera A, Tedesco F, Peyvandi F. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity. 2021;116:102560. https://doi.org/10.1016/j.jaut.2020.102560
  33. Lopez-Castaneda S, García-Larragoiti N, Cano-Mendez A, Blancas-Ayala K, Damian-Vázquez G, Perez-Medina AI, Chora-Hernández LD, Arean-Martínez C, Viveros-Sandoval ME. Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection. Clinical and Applied Thrombosis/Hemostasis. 2021;27:1076029621999099. https://doi.org/10.1177/1076029621999099
  34. Fernández S, Moreno-Castaño AB, Palomo M, Martinez-Sanchez J, Torramadé-Moix S, Téllez A, Ventosa H, Seguí F, Escolar G, Carreras E, Nicolás JM, Richardson E, García-Bernal D, Carlo-Stella C, Moraleda JM, Richardson PG, Díaz-Ricart M, Castro P. Distinctive Biomarker Features in The Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022;57(1):95-105.  https://doi.org/10.1097/SHK.0000000000001823
  35. Juneja GK, Castelo M, Yeh CH, Cerroni SE, Hansen BE, Chessum JE, Abraham J, Cani E, Dwivedi DJ, Fraser DD, Slessarev M, Martin C, McGilvray S, Gross PL, Liaw PC, Weitz JI, Kim PY, COVID-BEACONS investigators. Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. Journal of Thrombosis and Haemostasis. 2021;19(6):1546-1557. https://doi.org/10.1111/jth.15327
  36. Henry BM, Cheruiyot I, Benoit JL, Lippi G, Prohászka Z, Favaloro EJ, Benoit SW. Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study. Seminars in thrombosis and hemostasis. Seminars in Thrombosis and Hemostasis. 2021;47(4):451-455.  https://doi.org/10.1055/s-0040-1722308
  37. Campbell RA, Hisada Y, Denorme F, Grover SP, Bouck EG, Middleton EA, Wolberg AS, Rondina MT, Mackman N. Comparison of the coagulopathies associated with COVID-19 and sepsis. Research and Practice in Thrombosis and Haemostasis. 2021;5(4):e12525. https://doi.org/10.1002/rth2.12525
  38. Francischetti IMB, Toomer K, Zhang Y, Jani J, Siddiqui Z, Brotman DJ, Hooper JE, Kickler TS. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine. 2021;39:101069. https://doi.org/10.1016/j.eclinm.2021.101069
  39. Marchetti M, Gomez-Rosas P, Sanga E, Gamba S, Verzeroli C, Russo L, Restuccia F, Schieppati F, Bonanomi E, Rizzi M, Fagiuoli S, D’Alessio A, Lorini L, Falanga A. Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction. TH Open. 2021;5(3):253-263.  https://doi.org/10.1055/s-0041-1731711
  40. Bertolin AJ, Dalçóquio TF, Salsoso R, de Furtado MRH, Kalil-Filho R, Hajjar LA, Siciliano RF, Kallás EG, Baracioli LM, Lima FG, Giraldez RR, Cavalheiro-Filho C, Vieira A, Strunz CMC, Giugliano RP, Tantry US, Gurbel PA, Nicolau JC. Platelet Reactivity and Coagulation Markers in Patients with COVID-19. Advances in Therapy. 2021;38(7):3911-3923. https://doi.org/10.1007/s12325-021-01803-w
  41. Martín-Rojas RM, Chasco-Ganuza M, Casanova-Prieto S, Delgado-Pinos VE, Pérez-Rus G, Duque-González P, Sancho M, Díez-Martín JL, Pascual-Izquierdo C. A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients. Blood Coagulation & Fibrinolysis. 2021;32(7):458-467.  https://doi.org/10.1097/MBC.0000000000001068.
  42. Andrianto, Al-Farabi MJ, Nugraha RA, Marsudi BA, Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Microvascular Research. 2021;138:104224. https://doi.org/10.1016/j.mvr.2021.104224
  43. von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundström A, Magnusson M, Mackman N, Thalin C, Lisman T. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Advances. 2021;5(3):756-759.  https://doi.org/10.1182/bloodadvances.2020003968
  44. Henry BM, Benoit SW, Hoehn J, Lippi G, Favaloro EJ, Benoit JL. Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis. 2020;46(7):859-862.  https://doi.org/10.1055/s-0040-1715454
  45. Della-Morte D, Pacifici F, Ricordi C, Massoud R, Rovella V, Proietti S, Iozzo M, Lauro D, Bernardini S, Bonassi S, Di Daniele N. Low level of plasminogen increases risk for mortality in COVID-19 patients. Cell Death & Disease. 2021;12(8):773. 
  46. Wu Y, Wang T, Guo C, Zhang D, Ge X, Huang Z, Zhou X, Li Y, Peng Q, Li J. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. QJM: An International Journal of Medicine. 2020;113(8):539-545.  https://doi.org/10.1093/qjmed/hcaa121
  47. Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Molecular Cell. 2020;78(4):779-784.e5.  https://doi.org/10.1016/j.molcel.2020.04.022
  48. Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: A plasmin paradox. Journal of Thrombosis and Haemostasis. 2020;18(9):2118-2122. https://doi.org/10.1111/jth.14960
  49. Umemura Y, Yamakawa K, Kiguchi T, Nishida T, Kawada M, Fujimi S. Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy. Journal of Clinical Medicine. 2020;9(9):2875. https://doi.org/10.3390/jcm9092875
  50. Jin X, Duan Y, Bao T, Gu J, Chen Y, Li Y, Mao S, Chen Y, Xie W. The values of coagulation function in COVID-19 patients. PloS One. 2020;15(10):e0241329. https://doi.org/10.1371/journal.pone.0241329
  51. von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundström A, Rudberg A-S, Magnusson M, Mackman N, Thalin C, Lisman T. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Research and Practice in Thrombosis and Haemostasis. 2021;5(1):132-141.  https://doi.org/10.1002/rth2.12462
  52. Bouck EG, Denorme F, Holle LA, Middelton EA, Blair AM, de Laat B, Schiffman JD, Yost CC, Rondina MT, Wolberg AS, Campbell RA. COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(1):401-414.  https://doi.org/10.1161/ATVBAHA.120.315338
  53. Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L, David JS, Bonnet A, Negrier C, Dargaud Y. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. Journal of Thrombosis and Haemostasis. 2020;18(9):2215-2219. https://doi.org/10.1111/jth.15016
  54. Blasi A, von Meijenfeldt FA, Adelmeijer J, Calvo A, Ibañez C, Perdomo J, Reverter JC, Lisman T. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. Journal of Thrombosis and Haemostasis. 2020;18(10):2646-2653. https://doi.org/10.1111/jth.15043
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.